Skip to main content

Table 2 Demographic and clinical characteristics just before treatment start in patients with rheumatoid arthritis

From: Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study

Parameter

Men

Women

Pvalue

Patients, n (%)

402 (21%)

1510 (79%)

 

Age at treatment start, years

54.7 (13.7)

54.6 (14.5)

0.93

Disease duration, years

14.7 (10.8)

15.9 (11.2)

0.06

ESR, mm/h

30.1 (21.9)

33.1 (23.3)

0.022,3

CRP, mg/l

25.5 (30.1)

24.9 (31.4)

0.73

Physician global assessment

2.2 (0.8)

2.3 (0.7)

0.38

Patient global assessment

54.3 (24.3)

58.7 (24.1)

0.00*

Pain

54.8 (23.9)

56.9 (24.2)

0.16

Swollen joint count

9.1 (5.9)

8.8 (5.5)

0.36

Tender joint count

7.8 (6.3)

8.7 (6.1)

0.013,4

HAQ

1.13 (0.68)

1.34 (0.68)

0.003,4

DAS28

5.07 (1.37)

5.39 (1.21)

0.003,4

DAS28-CRP

4.87 (1.25)

5.06 (1.14)

0.013,4

EQ-5D

0.49 (0.36)

0.50 (0.30)

0.89

  1. Abbreviations: ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; HAQ, Health Assessment Questionnaire; DAS28, Disease Activity Score using 28 joints; DAS28-CRP, DAS28 using CRP; EQ-5D, EuroQol five dimensions utility score.
  2. 1Values are mean (SD), except for the first row.
  3. 2Mann-whitney U-test.
  4. 3Significant P values.
  5. 4Independent samples t-test